Literature DB >> 23506058

TLR3 agonists and proinflammatory antitumor activities.

Sherven Sharma, Li Zhu, Michael Davoodi, Marni Harris-White, Jay M Lee, Maie St John, Ravi Salgia, Steven Dubinett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23506058      PMCID： PMC3758767          DOI： 10.1517/14728222.2013.781585

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN： 1472-8222            Impact factor:   6.902


× No keyword cloud information.
  17 in total

Review 1.  Bugs as drugs for cancer.

Authors:  Eleanor J Cheadle; Andrew M Jackson
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

2.  Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance.

Authors:  Arnold I Chin; Andrea K Miyahira; Anthony Covarrubias; Juli Teague; Beichu Guo; Paul W Dempsey; Genhong Cheng
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

Review 3.  Innate recognition of viruses.

Authors:  Andreas Pichlmair; Caetano Reis e Sousa
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

4.  Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer.

Authors:  Touko Inao; Nanae Harashima; Hiroyuki Monma; Shinji Okano; Masayuki Itakura; Tsuneo Tanaka; Yoshitsugu Tajima; Mamoru Harada
Journal:  Breast Cancer Res Treat       Date:  2011-12-28       Impact factor: 4.872

5.  TLR3 can directly trigger apoptosis in human cancer cells.

Authors:  Bruno Salaun; Isabelle Coste; Marie-Clotilde Rissoan; Serge J Lebecque; Toufic Renno
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

6.  Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism.

Authors:  Alessio Paone; Donatella Starace; Roberta Galli; Fabrizio Padula; Paola De Cesaris; Antonio Filippini; Elio Ziparo; Anna Riccioli
Journal:  Carcinogenesis       Date:  2008-06-19       Impact factor: 4.944

7.  A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.

Authors:  Nicholas Butowski; Kathleen R Lamborn; Bee L Lee; Michael D Prados; Timothy Cloughesy; Lisa M DeAngelis; Lauren Abrey; Karen Fink; Frank Lieberman; Minesh Mehta; H Ian Robins; Larry Junck; Andres M Salazar; Susan M Chang
Journal:  J Neurooncol       Date:  2008-10-11       Impact factor: 4.130

8.  A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors.

Authors:  R A Robinson; V T DeVita; H B Levy; S Baron; S P Hubbard; A S Levine
Journal:  J Natl Cancer Inst       Date:  1976-09       Impact factor: 13.506

9.  An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma.

Authors:  M J Hawkins; M Levin; E C Borden
Journal:  J Biol Response Mod       Date:  1985-12

10.  A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome.

Authors:  D R Strayer; W A Carter; I Brodsky; P Cheney; D Peterson; P Salvato; C Thompson; M Loveless; D E Shapiro; W Elsasser
Journal:  Clin Infect Dis       Date:  1994-01       Impact factor: 9.079
View more
  7 in total

Review 1.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

2.  Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma.

Authors:  Kevin D McCormick; Arundhati Ghosh; Sumita Trivedi; Lin Wang; Carolyn B Coyne; Robert L Ferris; Saumendra N Sarkar
Journal:  Carcinogenesis       Date:  2016-03-18       Impact factor: 4.944

3.  Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis.

Authors:  Camille Guillerey; Melvyn T Chow; Kim Miles; Stuart Olver; Jaclyn Sceneay; Kazuyoshi Takeda; Andreas Möller; Mark J Smyth
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

4.  Concomitant type I IFN and M-CSF signaling reprograms monocyte differentiation and drives pro-tumoral arginase production.

Authors:  Yuanyuan Tong; Luyang Zhou; Limin Yang; Panpan Guo; Yanlan Cao; F Xiao-Feng Qin; Jianghuai Liu
Journal:  EBioMedicine       Date:  2018-12-07       Impact factor: 8.143

Review 5.  Selection of adjuvants for vaccines targeting specific pathogens.

Authors:  Indranil Sarkar; Ravendra Garg; Sylvia van Drunen Littel-van den Hurk
Journal:  Expert Rev Vaccines       Date:  2019-04-22       Impact factor: 5.217

Review 6.  Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy.

Authors:  Ji-Yoon Noh; Suk Ran Yoon; Tae-Don Kim; Inpyo Choi; Haiyoung Jung
Journal:  J Immunol Res       Date:  2020-01-04       Impact factor: 4.818

Review 7.  Trial watch: TLR3 agonists in cancer therapy.

Authors:  Julie Le Naour; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2020-06-02       Impact factor: 8.110
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.